ethyl 1-benzyl-5-bromo-1H-indole-2-carboxylate | 198277-56-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: ethyl 1-benzyl-5-bromo-1H-indole-2-carboxylate
• 英文别名: 1-benzyl-5-bromo-1H-indole-2-carboxylic acid ethyl ester；5-bromo-1-benzylindole-2-carboxylic acid ethyl ester；ethyl 5-bromo-1-benzyl-1H-indole-2-carboxylate；ethyl 1-benzyl-5-bromoindole-2-carboxylate
• CAS: 198277-56-4
• 化学式: C₁₈H₁₆BrNO₂
• 分子量: 358.235
• InChiKey: MJNSKTVQAZTLTO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  31.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  ethyl 1-benzyl-5-bromo-1H-indole-2-carboxylate 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 (1-benzyl-5-bromo-1H-indol-2-yl)-methanol
  参考文献：
  名称：

  Indolyl derivatives as liver-X-receptor (LXR) modulators

  摘要：

  这项发明涉及式(I)的化合物： 以及其药学上可接受的盐和药学上可接受的酯，其中R 1 ，R 2 ，R 3 ，R 4 ，R 5 ，R 6 ，A，m，n和p的定义如权利要求书中所述。 这些化合物可用作治疗糖尿病等疾病的药物组合物。

  公开号：

  US20050245515A1
• 作为产物：
  描述：

  5-溴吲哚-2-羧酸乙酯 、 溴甲苯 在 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 ethyl 1-benzyl-5-bromo-1H-indole-2-carboxylate
  参考文献：
  名称：

  [4 + 2]环化或丢失重排：铑催化发散合成具有抗癌活性的咔啉衍生物

  摘要：

  已经实现了一种不寻常的铑催化的 C–H 活化/Lossen 重排/oxa-Michael 加成串联环化以及众所周知的可调 C–H 活化/[4 + 2] 环化，从而导致区域-、化学-和非对映选择性获得多种五环α-咔啉和β-咔啉-1-酮衍生物，产率中等至良好，具有显着的抗癌活性。

  DOI：

  10.1021/acs.orglett.4c01050

文献信息

• A Class of Amide Ligands Enable Cu-Catalyzed Coupling of (Hetero)aryl Halides with Sulfinic Acid Salts under Mild Conditions
  作者：Jinlong Zhao、Songtao Niu、Xi Jiang、Yongwen Jiang、Xiaojing Zhang、Tiemin Sun、Dawei Ma

  DOI：10.1021/acs.joc.8b00888

  日期：2018.6.15

  The amide derived from 4-hydroxy-l-proline and 2,6-dimethylaniline is a powerful ligand for Cu-catalyzed coupling of (hetero)aryl halides with sulfinic acid salts, allowing the formation of a wide range of (hetero)aryl sulfones from the corresponding (hetero)aryl halides at considerably low catalytic loadings. The coupling of (hetero)aryl iodides and sodium methanesulfinate proceeds at room temperature

  衍生自4-羟基-1-脯氨酸和2,6-二甲基苯胺的酰胺是Cu催化（杂）芳基卤化物与亚磺酸盐偶联的强配体，可形成各种（杂）芳基砜由相应的（杂）芳基卤化物以低的催化负载量得到。（杂）芳基碘化物和甲烷亚磺酸钠的偶联在室温下仅用0.5mol％的CuI和配体进行，代表了在低催化负载和室温下Cu催化的芳基化的第一个实例。
• Heterocyclic .beta.-adrenergic agonists
  申请人：Pfizer Inc.

  公开号：US05843972A1

  公开（公告）日：1998-12-01

  The present invention relates to certain compounds of the formula (I) the racemic-enantiomeric mixtures and optical isomers of said compounds and the pharmaceutically acceptable salts or prodrugs thereof, depicted below, which are .beta.-adrenergic receptor agonists and accordingly have utility as, inter alia, hypoglycemic and antiobesity agents. More specifically, the compounds of the instant invention are selective agonists of .beta..sub.3 -adrenergic receptor. The invention also relates to methods of use for the compounds and to pharmaceutical compositions containing them. The compounds of the present invention also possess utility for increasing lean meat deposition and/or improving the lean meat to fat ratio in animals, e.g., ungulate animals, companion animals and poultry. The compounds have the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, Y and Z are as defined in the specification.

  本发明涉及以下公式（I）的某些化合物，其为该化合物的外消旋混合物和光学异构体以及其药学上可接受的盐或前药，如下图所示，这些化合物是β-肾上腺素受体激动剂，因此具有降糖和抗肥胖剂等用途。更具体地说，本发明的化合物是β3-肾上腺素受体的选择性激动剂。本发明还涉及这些化合物的使用方法以及含有它们的药物组合物。本发明的化合物还具有增加瘦肉沉积和/或改善动物（例如有蹄动物、伴侣动物和家禽）的瘦肉与脂肪比例的用途。这些化合物的公式如下： 其中R.sup.1、R.sup.2、R.sup.3、R.sup.4、R.sup.5、Y和Z如规范中所定义。
• Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
  申请人：Wyeth

  公开号：US20030125371A1

  公开（公告）日：2003-07-03

  This invention provides compounds of the formula: 1 wherein: X is a chemical bond, —CH 2 — or —C(O)—; R 1 is alkyl, cycloalkyl, —CH 2 -cycloalkyl, pyridinyl, —CH 2 -pyridinyl, phenyl or benzyl; R 2 is H, alkyl, cycloalkyl, —CH 2 -cycloalkyl, or perfluoroalkyl; R 3 is H, halo, alkyl, perfluoroalkyl, alkoxy, cycloalkyl, —CH 2 -cycloalkyl, —NH 2 , or —NO 2 ; R 4 is optionally substituted phenyl, benzyl, benzyloxy, pyridinyl, or —CH 2 -pyridinyl, or the salt or ester forms thereof, as well as methods for using the compounds as inhibitors of plasminogen activator inhibitor-1 (PAI-1) and as therapeutic compositions for treating conditions resulting from fibrinolytic disorders such as deep vein thrombosis and coronary heart disease, and pulmonary fibrosis.

  这项发明提供了以下结构的化合物：其中：X是化学键，-CH2-或-C(O)-；R1是烷基、环烷基、-CH2-环烷基、吡啶基、-CH2-吡啶基、苯基或苄基；R2是H、烷基、环烷基、-CH2-环烷基或全氟烷基；R3是H、卤素、烷基、全氟烷基、烷氧基、环烷基、-CH2-环烷基、-NH2或-NO2；R4是可选择地取代的苯基、苄基、苄氧基、吡啶基或-CH2-吡啶基，或其盐或酯形式，以及使用这些化合物作为纤溶酶原激活抑制剂-1（PAI-1）的抑制剂和作为治疗配方，用于治疗由纤溶障碍引起的疾病，如深静脉血栓形成、冠心病和肺纤维化。
• [EN] SUBSTITUTED INDOLE ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1)<br/>[FR] DERIVES D'ACIDE INDOLE SUBSTITUE UTILISES EN TANT QU'INHIBITEURS DE L'INHIBITEUR-1 (PAI-1) DE L'ACTIVATEUR PLASMINOGENE
  申请人：WYETH CORP

  公开号：WO2003000253A1

  公开（公告）日：2003-01-03

  This invention provides compounds of the formula : (I) wherein: X is a chemical bond, -CH2- or -C(O)-; R1 is alkyl, cycloalkyl, -CH2-cycloalkyl, pyridinyl, -CH2-pyridinyl, phenyl or benzyl; R2 is H, alkyl, cycloalkyl, -CH2-cycloalkyl, or perfluoroalkyl; R3 is H, halo, alkyl, perfluoroalkyl, alkoxy, cycloalkyl, -CH2-cycloalkyl, -NH2, or -NO2; R4 is optionally substituted phenyl, benzyl, benzyloxy, pyridinyl, or -CH2-pyridinyl, or the salt or ester forms thereof, as well as methods for using the compounds as inhibitors of plasminogen activator inhibitor-1 (PAI-1) and as therapeutic compositions for treating conditions resulting from fibrinolytic disorders such as deep vein thrombosis and coronary heart disease, and pulmonary fibrosis, and processes for their preparation.

  本发明提供了式（I）的化合物：其中：X是化学键，-CH2-或-C（O）-; R1是烷基，环烷基，-CH2-环烷基，吡啶基，-CH2-吡啶基，苯基或苄基; R2是H，烷基，环烷基，-CH2-环烷基或全氟烷基; R3是H，卤素，烷基，全氟烷基，烷氧基，环烷基，-CH2-环烷基，-NH2或-NO2; R4是可选取代的苯基，苄基，苄氧基，吡啶基或-CH2-吡啶基，或其盐或酯形式，以及将该化合物用作纤溶酶原激活物抑制剂-1（PAI-1）的抑制剂和用作治疗由于纤溶失调引起的疾病的治疗组合物，例如深静脉血栓和冠心病，肺纤维化以及其制备方法。
• Substituted dihydropyrano indole-3,4-dione derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
  申请人：Elokdah M. Hassan

  公开号：US20050113436A1

  公开（公告）日：2005-05-26

  Compounds of formula (I) and II) are provided wherein: X is an alkali metal or a basic amine moiety; R 1 is alkyl, cycloalkyl, —CH 2 -cycloalkyl, pyridinyl, —CH 2 -pyridinyl, phenyl or benzyl, the rings of these groups being optionally substituted; R 2 is H, halogen, alkyl, perfluoroalkyl, alkoxy, cycloalkyl, —CH 2 -cycloalkyl, —NH 2 , or —NO 2 ; R 3 is phenyl, benzyl, benzyloxy, pyridinyl, or —CH 2 -pyridinyl, with the rings of these groups being optionally substituted; or a pharmaceutically acceptable salt or ester form thereof, as well as pharmaceutical compositions and methods using these compounds as inhibitors of plasminogen activator inhibitor-1 (PAI-1) and as therapeutic compositions for treating conditions resulting from fibrinolytic disorders such as deep vein thrombosis and coronary heart disease, and pulmonary fibrosis.

  提供了化合物(I)和(II)的公式，其中：X是碱金属或碱性胺基；R1是烷基、环烷基、—CH2-环烷基、吡啶基、—CH2-吡啶基、苯基或苄基，这些基团的环可以有取代基；R2是氢、卤素、烷基、全氟烷基、烷氧基、环烷基、—CH2-环烷基、—NH2或—NO2；R3是苯基、苄基、苄氧基、吡啶基或—CH2-吡啶基，这些基团的环可以有取代基；或其药学上可接受的盐或酯形式，以及使用这些化合物作为纤溶酶原激活抑制剂-1（PAI-1）的抑制剂和治疗深静脉血栓和冠心病等纤溶障碍症状及肺纤维化的治疗组合物和方法。